Ketogenic diet and childhood neurological disorders other than epilepsy: an overview

Expert Review of Neurotherapeutics

Volumn 17, Issue 5, 2017, Pages 461-473

  Verrotti, Alberto ^a   Iapadre, Giulia ^a   Pisano, Simone ^b   Coppola, Giangennaro ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

alternating hemiplegia; autism; brain tumors; Ketogenic diet; migraine; mitochondrial diseases

Indexed keywords

PYRUVATE DEHYDROGENASE;

AUTISM; BRAIN CANCER; BRAIN TUMOR; CHILD; CHILDHOOD DISEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPILEPSY; HEMIPLEGIA; HUMAN; KETOGENIC DIET; MIGRAINE; NEUROLOGIC DISEASE; NONHUMAN; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; REVIEW; SYMPTOM; DIET THERAPY; MENTAL DISEASE;

AUTISM SPECTRUM DISORDER; EPILEPSY; HEMIPLEGIA; HUMANS; KETOGENIC DIET; NEURODEVELOPMENTAL DISORDERS;

EID: 85016274431     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1080/14737175.2017.1260004     Document Type: Review

References (105)

1. Branco AF, Ferreira A, Simões RF, et al. Ketogenic diets:from cancer to mitochondrial diseases and beyond. Eur J Clin Invest. 2016;46:285–298.
2. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy:a randomized controlled trial. Lancet Neurol. 2008;7:500–506.
3. Liu YM, Wang HS., Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J. 2013;36:9–15.
4. Kossoff E, Zupec-Kania B, Amark P, et al. Optimal clinical management of children receiving the ketogenic diet:recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009;50:304–317.•• A paper of great interest:the first attempt to create a consensus statement regarding the clinical management of KD.
5. Wibisono C, Rowe N, Beavis E, et al. Ten-year single-center experience of the ketogenic diet:factors influencing efficacy, tolerability, and compliance. J Pediatr. 2015;166(4):1030–1036.
6. Kang HC, Chung DE, Kim DW, et al. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004;45:1116–1123.• A manuscript of high value regarding side effects of KD for intractable epilepsy.
7. Coppola G, Verrotti A, Ammendola E, et al. Ketogenic diet for the treatment of catastrophic epileptic encephalopathies in childhood. Eur J Paediatr Neurol. 2010;14:229–234.
8. Groomes LB, Pyzik PL, Turner Z, et al. Do patients with absence epilepsy respond to ketogenic diets? J Child Neurol. 2011;26:160–165.
9. Kossoff EH, Rowley H, Sinha SR, et al. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia. 2008;49:316–319.
10. Kim DY, Simeone KA, Simeone TA, et al. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. Ann Neurol. 2015;78:77–87.•• A study of notable interest investigating physiopathological mechanisms beyond anti-seizure effects of ketone bodies.
11. Kang HC, Lee YM, Kim HD, et al. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia. 2007;48:82–88.•• A study assessing the safety and efficacy of KD in RCC defects, a new field of growing interest.
12. Vila-Pueyo M, Pons R, Raspall-Chaure M, et al. Clinical and genetic analysis in alternating hemiplegia of childhood:ten new patients from Southern Europe. J Neurol Sci. 2014;344:37–42.
13. Roubergue A, Philibert B, Gautier A, et al. Excellent response to a ketogenic diet in a patient with alternating hemiplegia of childhood. JIMD Rep. 2015;15:7–12.
14. Ulate-Campos A, Fons C, Artuch R, et al. Alternating hemiplegia of childhood with a de novo mutation in ATP1A3 and changes in SLC2A1 responsive to a ketogenic diet. Pediatr Neurol. 2014;50:377–379.
15. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior:pilot study. J Child Neurol. 2003;18:113–118.
16. Spilioti M, Evangeliou AE, Tramma D, et al. Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD). Front Hum Neurosci. 2013;7:858.
17. Nebeling LC, Miraldi F, Shurin SB, et al. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients:two case reports. J Am Coll Nutr. 1995;14:202–208.
18. Kalamian M, Zupec-Kania B, Favara BE, et al. Ketogenic diet as adjunctive therapy for brain tumors. First international symposium on the ketogenic diet for epilepsy and other neurological disorders Barrows Neurological Institute, Phoenix Az 2008:Poster presentation.
19. Rieger J, Bähr O, Maurer GD, et al. ERGO:a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44:1843–1852.
20. Champ CE, Palmer JD, Volek JS, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 2014;117:125–131.• A manuscript of great interest because of recent knowledge about KD and malignant brain tumors.
21. Schwartz K, Chang HT, Nikolai M, et al. Treatment of glioma patients with ketogenic diets:report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab. 2015;3(1):3.
22. Di Lorenzo C, Currà A, Sirianni G, et al. Diet transiently improves migraine in two twin sisters:possible role of ketogenesis? Funct Neurol. 2013;28:305–308.
23. Di Lorenzo C, Coppola G, Sirianni G, et al. Migraine improvement during short lasting ketogenesis:a proof-of-concept study. Eur J Neurol. 2015;22:170–177.
24. Kossoff EH, Huffman J, Turner Z, et al. Use of the modified Atkins diet for adolescents with chronic daily headache. Cephalgia. 2010;30:1014–1016.
25. Di Mauro S, Schon EA, Carelli V, et al. The clinical maze of mitochondrial neurology. Nat Rev Neurol. 2013;9:429–444.
26. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol. 2008;63:35–39.
27. Elliott HR, Samuels DC, Eden JA, et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet. 2008;83:254–260.
28. Chinnery PF, Johnson MA, Wardell TM, et al. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol. 2000;48:188–193.
29. Kisler JE, Whittaker RG, McFarland R. Mitochondrial diseases in childhood:a clinical approach to investigation and management. Dev Med Child Neurol. 2010;52:422–433.
30. Govindaraj P, Khan NA, Gopalakrishna P, et al. Mitochondrial dysfunction and genetic heterogeneity in chronic periodontitis. Mitochondrion. 2011;11:504–512.
31. Viscomi C, Bottami B, Zeviani M. Emerging concepts in the therapy of mitochondrial disease. Biochim Biophys Acta. 2015;1847(6-7):544-557.
32. Nunnari J, Suomalainen A. Mitochondria:in sickness and in health. Cell. 2012;148:1145–1159.
33. Gilkerson RW, De Vries RL, Lebot P, et al. Mitochondrial autophagy in cells with mtDNA mutations results from the synergistic loss of transmembrane potential and mRORC1 inhibition. Hum Mol Genet. 2012;21:978–990.
34. Danial NN, Hartman AL, Stafstrom CE, et al. How does the ketogenic diet work? Four potential mechanisms. J Child Neurol. 2013;28:1027–1033.
35. Hartman AL, Rho JM. The biochemical basis of dietary therapies for neurological disorders. In:Neal EG, editor. Dietary treatment of epilepsy:practical implementation of ketogenic therapy. Oxford:Wiley-Blackwell; 2012. p. 34–44.
36. Santra S, Gilkerson RW, Davidson M, et al. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol. 2004;56:662–669.• A manuscript of notable value for new fields of KD investigation in vitro.
37. Steriade C, Andrade DM, Faghfoury H, et al. Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet. Pediatr Neurol. 2014;50:498–502.
38. Krebs P, Fan W, Chen YH, et al. Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet. Proc Natl Acad Sci USA. 2011;108:19678–19682.
39. Ahola-Erkkilä S, Carroll CJ, Peltola-Mjösund K, et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet. 2010;19:1974–1984.
40. Lissens W, Meirleir DL, Sebeca S, et al. Mutation in the X-linked pyruvatedehydrogenase (E1) a subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum Mutat. 2000;15:209–219.
41. Cederbaum SD, Blass JP, Minkoff N, et al. Sensitivity to carbohydrate in a patient with familial intermittent lactic acidosis and pyruvate dehydrogenase deficiency. Pediatr Res. 1976;10:713–720.
42. Singhi P, De Meirleir L, Lissens W, et al. Pyruvate dehydrogenase-e1α deficiency presenting as recurrent demyelination:an unusual presentation and a novel mutation. JIMD Rep. 2013;10:107–111.
43. Wexler ID, Hemalatha SG, McConnell J, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology. 1997;49:1655–1661.
44. Falk RE, Cederbaum SD, Blass JP, et al. Ketogenic diet in the management of pyruvate dehydrogenase deficiency. Pediatrics. 1976;58:713–721.• A paper of high interest because providing useful information about the role of KD in the management of PDHD.
45. Wijburg FA, Barth PG, Bindoff LA, et al. Leigh syndrome associated with deficiency of the pyruvate dehydrogenase complex:results of treatment with a ketogenic diet. Neuropediatrics. 1992;23:147–152.
46. El-Gharbawy AH, Boney A, Young SP, et al. Follow-up of a child with pyruvate dehydrogenase deficiency on a less restrictive ketogenic diet. Mol Genet Metab. 2011;102:214–215.
47. Di Pisa V, Cecconi I, Gentile V, et al. Case report of pyruvate dehydrogenase deficiency with unusual increase of fats during ketogenic diet treatment. J Child Neurol. 2012;27:1593–1596.
48. Laugel V, This-Bernd V, Cormier-Daire V, et al. Early-onset ophthalmoplegia in Leigh-like syndrome due to NDUFV1 mutations. Pediatr Neurol. 2007;36:54–57.
49. Seo JH, Lee YM, Lee JS, et al. A case of Ohtahara syndrome with mitochondrial respiratory chain complex I deficiency. Brain Dev. 2010;32:253–257.
50. Joshi CN, Greenberg CR, Mhanni AA, et al. Ketogenic diet in Alpers- Huttenlocher syndrome. Pediatr Neurol. 2009;40:314–316.
51. Weber TA, Antognetti MR, Stacpoole PW. Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency. J Pediatr. 2001;138:390–395.• A critical analysis of the use of KD in PDHD, of interest.
52. Orfali KA, Fryer LGD, Holness MJ, et al. Long-term regulation of pyruvate dehydrogenase kinase by high fat feeding. FEBS Lett. 1997;336:501–505.
53. Dietschy JM, Woollett LA, Spady DK. Dietary fatty acids and the regulation of plasma low-density lipoprotein cholesterol levels. Artheroscler Rev. 1991;23:7–18.
54. Fryer LGD, Orfali KA, Holness MJ, et al. The longterm regulation of skeletal muscle pyruvate dehydrogenase kinase by dietary lipid is dependent on fatty acid composition. Eur J Biochem. 1995;229:741–748.
55. Nordli DR, DeVivo DC. The ketogenic diet. In:Wyllie E, editor. The treatment of epilepsy. 3rd ed. Philadelphia (PA):Lippincott Williams & Wilkins; 2001. p. 1001–1006.
56. Kang HC, Kim YJ, Kim DW, et al. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy:Korean multicentric experience. Epilepsia. 2005;46:272–279.
57. Bastin J. Regulation of mitochondrial fatty acid beta-oxidation in human:what can we learn from inborn fatty acid beta-oxidation deficiencies? Biochimie. 2014;96:113–120.
58. Bennett MJ. Pathophysiology of fatty acid oxidation disorders. J Inherit Metab Dis. 2010;33:533–537.
59. Sperl W, Fleuren L, Freisinger P, et al. The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders. J Inherit Metab Dis. 2015;38:391–403.
60. Suman B, Kripamoy A. Pyruvate dehydrogenase complex deficiency and its relationship with epilepsy frequency. Epilepsy Res. 2015;116:40–52.
61. Sweney MT, Silver K, Gerard-Blanluet M, et al. Alternating hemiplegia of childhood:early characteristics and evolution of a neurodevelopmental syndrome. Pediatrics. 2009;123:534–541.
62. Panagiotakaki E, Gobbi G, Neville B, et al. Evidence of a non-progressive course of alternating hemiplegia of childhood:study of a large cohort of children and adults. Brain. 2010;133:3598–3610.
63. Heinzen EL, Swoboda KJ, Hitomi Y, et al. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet. 2012;44:1030–1034.
64. Rosewich H, Thiele H, Ohlenbusch A, et al. Heterozygous de-novo mutations in ATP1A3 in patients with alternating hemiplegia of childhood:a whole-exome sequencing gene identification study. Lancet Neurol. 2012;11:764–773.
65. Ishii A, Saito Y, Mitsui J, et al. Identification of ATP1A3 mutations by exome sequencing as the cause of alternating hemiplegia of childhood in Japanese patients. PLoS One. 2013;8(2):e56120.
66. Mikati MA, Kramer U, Zupanc ML, et al. Alternating hemiplegia of childhood:clinical manifestations and long-term outcome. Pediatr Neurol. 2000;23:134–141.
67. Ito Y, Oguni H, Ito S, et al. A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome. Dev Med Child Neurol. 2011;53:658–663.
68. Klepper J, Scheffer H, Leiendecker B, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome:a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics. 2005;36:302–308.
69. De Giorgis V, Veggiotti P. GLUT1 deficiency syndrome 2013:current state of the art. Seizure. 2013;22:803–811.
70. Sasaki M, Sakuma H, Fukushima A, et al. Abnormal cerebral glucose metabolism in alternating hemiplegia of childhood. Brain Dev. 2009;31:20–26.
71. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007:results of EUROCARE-5–a population-based study. Lancet Oncol. 2014;15:35–47.
72. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults:a “state of the science” review. Neuro Oncol. 2014;16:896–913.
73. Johnson KJ, Cullen J, Barnholtz-Sloan JS, et al. Childhood brain tumor epidemiology:a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev. 2014;23:2716–2736.
74. Kapelner A, Vorsanger M. Starvation of cancer via induced ketogenesis and severe hypoglycemia. Med Hypotheses. 2015;84:162–168.
75. Luna B, Bhatia S, Yoo C, et al. Proteomic and mitochondrial genomic analyses of pediatric brain tumors. Mol Neurobiol. 2015;52:1341–1363.
76. Marsh J, Mukherjee P, Seyfried TN. Drug/diet synergy for managing malignant astrocytoma in mice:2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab (Lond). 2008;25:5–33.
77. Stafford P, Abdelwahab MG, Kim Do Y, et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;10:7–74.
78. Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012;7:e36197.• A study of great impact regarding new direction about the usefulness of KD in the management of brain tumors.
79. Dang MT, Wehrli S, Dang CV, et al. The ketogenic diet does not affect growth of hedgehog pathway medulloblastoma in mice. PLoS One. 2015;10:e0133633.
80. Woolf EC, Curley KL, Liu Q, et al. The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One. 2015;10:e0130357.
81. Chu-Shore CJ, Thiele EA. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. Brain Dev. 2010;32:318–322.
82. Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9:190–204.
83. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
84. Lampl C. Childhood-onset cluster headache. Pediatr Neurol. 2002;27:138–140.
85. Yorns WR, Jr, Hardison HH. Mitochondrial dysfunction in migraine. Semin Pediatr Neurol. 2013;20:188–193.
86. Ross-Araujo D, Stuart S, Lea RA, et al. Epigenetics and migraine; complex mitochondrial interactions contributing to disease susceptibility. Gene. 2014;543:1–7.
87. Wheless JW. History of the ketogenic diet. Epilepsia. 2008;49:3–5.
88. Cullingford T. The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot Essent Fatty Acids. 2004;70:253–264.• A paper of remarkable value; it provides a detailed analysis of molecular mechanisms involved in the efficacy of KD in neurological disorders.
89. Maalouf Sullivan PG, Davis L, Kim DY, et al. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 2007;145:256–264.
90. de Almeida Rabello Oliveira M, da Rocha Ataíde T, de Oliveira SL, et al. Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci Lett. 2008;434:66–70.
91. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Washington, DC:American Psychiatric Association; 2013.
92. Accordino RE, Kidd C, Politte LC, et al. Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother. 2016;17:937–952.
93. Longden E, Read J. Assessing and reporting the adverse effects of antipsychotic medication:a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 2016;39:29–39.
94. Mantis JG, Fritz CL, Marsh J, et al. Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets. Epilepsy Behav. 2009;15:133–141.
95. Ruskin DN, Svedova J, CoteJ L, et al. Ketogenic diet improves core symptoms of autism in BTBR mice. PloS One. 2013;8:e65021.
96. Castro K, Baronio D, Perry IS, et al. The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid. Nutr Neurosci. 2016 Feb 9:1–8. doi:10.1080/1028415X.2015.1133029.
97. Hara H. Autism and epilepsy:a retrospective follow-up study. Brain Dev. 2007;29:486–490.
98. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1:352–358.
99. El Achkar CM, Spence SJ. Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy. Epilepsy Behav. 2015;47:183–190.
100. Shavelle RM, Strauss DJ, Pickett J. Causes of death in autism. J Autism Dev Disord. 2001;31:569–576.
101. Jabbari K, Nürnberg P. A genomic view on epilepsy and autism candidate genes. Genomics. 2016;108:31–36.
102. Frye RE, Rossignol DA. Identification and treatment of pathophysiological comorbidities of autism spectrum disorder to achieve optimal outcomes. Clin Med Insights Pediatr. 2016;10:43–56.
103. Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2012 Mar 14;3:CD001903.
104. Frye RE, Sreenivasula S, Adams JB. Traditional and non-traditional treatments for autism spectrum disorder with seizures:an on-line survey. BMC Pediatr. 2011;11:37.
105. Herbert MR, Buckley JA. Autism and dietary therapy:case report and review of the literature. J Child Neurol. 2013;28:975–982.